NCT05901324View on ClinicalTrials.gov

Efficacy of Lenalidomide Maintenance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma: a Phase II, Open-label, Single-arm Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

May 31, 2031

Study Completion Date

May 31, 2031

Conditions
Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
Interventions
RADIATION

intensity-modulated radiotherapy (IMRT)

1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER